Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
Recruiting
G1 Therapeutics, Inc.
Phase 3
2021-04-15
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating
the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and
carboplatin in patients receiving first- or second-line treatment for locally advanced
unresectable/metastatic TNBC.
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
Recruiting
G1 Therapeutics, Inc.
Phase 2
2021-04-16
This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial
evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel
in patients with mNSCLC treated in the 2nd or 3rd line setting.
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
Recruiting
G1 Therapeutics, Inc.
Phase 2
2021-06-04
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and
efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib
administered with avelumab maintenance therapy compared with platinum-based chemotherapy
followed by avelumab maintenance therapy in patients receiving first-line treatment for
advanced/metastatic bladder cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
